Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. (ATTBF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
attbf · pe ratio · data through Sep 30, 2019
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Abattis Bioceuticals Corp. (ATTBF) measures how much investors pay for each dollar of the company's trailing earnings. ATTBF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.01.
Source: FMP · /ratios-ttm · /analyst-estimates · 2019-09-30
PE Ratio History
2008 – 2019 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Abattis Bioceuticals Corp.You ATTBF | $0M | N/A | — | -$0.01 |
 ARYx Therapeutics, Inc. ARYX | $0M | N/A | — | -$1.21 |
 Biome Grow Inc. BIOIF | $0M | N/A | — | -$0.10 |
 Cannabis Global, Inc. CBGL | $0M | N/A | — | -$0.00 |
 Psykey, Inc. CEOS | $0M | 0.32x | — | $0.01 |
 Instadose Pharma Corp. INSD | $0M | N/A | — | -$0.01 |
 Isodiol International Inc. ISOLF | $0M | N/A | — | -$2.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2019-09-30Latest FY2019 | — | $-0.01 | — | |
2018-09-30 FY2018 | — | $-0.24 | — | |
2017-09-30 FY2017 | — | $-0.05 | — | |
2016-09-30 FY2016 | — | $-0.02 | — | |
2015-09-30 FY2015 | — | $-0.06 | — | |
2014-09-30 FY2014 | — | $-0.16 | — | |
2013-09-30 FY2013 | — | $-0.04 | — | |
2012-09-30 FY2012 | — | $-0.09 | — | |
2011-09-30 FY2011 | — | $-0.14 | — | |
2010-09-30 FY2010 | — | $-0.15 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Abattis Bioceuticals Corp. (ATTBF) measures how much investors pay for each dollar of the company's trailing earnings. ATTBF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.01.
Frequently asked questions
ATTBF pe ratio · 6 questionsATTBF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.01. Data sourced from Financial Modeling Prep via ATTBF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Abattis Bioceuticals Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09